ReviewClinical rheumatology2024
Inflammation as a therapeutic target for osteoarthritis: A literature review of clinical trials.
Review in Clinical rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Efficacy of a Tumor Necrosis Factor Inhibitor in Chronic Low-Back Pain With Modic Type 1 Changes: A Randomized Controlled Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2025Trial
- Translating mechanobiology in osteoarthritis to biomaterial-informed therapeutic strategies.Mechanobiology in medicine · 2026Review
- Immune dysregulation in osteoarthritis: Mechanisms, biomarkers, and therapeutic opportunities.Journal of translational autoimmunity · 2026Review
- Key Inflammatory Pathways, Biomarkers, and Targeted Management Strategies in Primary Total Joint Arthroplasty: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Cross-Tissue Transcriptomic Convergence Identifies a Leuko-Cyte-Shared, Myeloid-Enriched Inflammatory Program in Frailty and Osteoarthritis.International journal of molecular sciences · 2026Article
- Cellular Products with Anti-Inflammatory Properties for the Treatment of Cartilage Lesions.International journal of molecular sciences · 2026Review
- Single Intra-Articular Anakinra (IL-1Ra) Versus Betamethasone in Rabbit Post-Traumatic Knee Osteoarthritis: IL-8 Suppression and Chondrocyte Viability.Cell biochemistry and function · 2026Article
- Modulation Effects of Reproductive Hormones on Oogenesis in a Collagenase-Induced Osteoarthritis Mouse Model.Biomedicines · 2026Article
- Optimized Centrifugation and Activation Protocol for the Preparation of Plasma Rich in Growth Factors in Pigs.Biomedicines · 2026Article
- Focus on the NLRP3 inflammasome: its role in the pathogenesis and therapeutic potential of inflammation-driven osteoarthritis.Frontiers in immunology · 2026Review
- Natural products and immune-cell responses in osteoarthritis: mechanisms, evidence maturity, and translational gaps.Frontiers in immunology · 2026Review
- Targeting synovial inflammation in knee osteoarthritis: translational insights for diagnosis and therapy.Journal of orthopaedic translation · 2026Review
- Heterogeneity in osteoarthritis radiotherapy: unresolved questions and the need for joint-specific evidence.Rheumatology international · 2025Article
- Article
- Article
- Article
- Targeting p21-Positive Senescent Chondrocytes via IL-6R/JAK2 Inhibition to Alleviate Osteoarthritis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Association between serum high-sensitivity C-reactive protein levels and osteoarthritis in adults from NHANES 2015 to 2018.Scientific reports · 2025Article
- Recent advances in injectable hydrogels for osteoarthritis treatments.Frontiers in bioengineering and biotechnology · 2025Review
- Targeting inflammation-metabolism crosstalk: current status and challenges of novel therapeutic strategies for osteoarthritis.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The burden of osteoarthritis (OA) is rapidly increasing with population aging, but there are still no approved disease-modifying drugs available. Accumulating evidence has shown that OA is a heterogeneous disease with multiple phenotypes, and it is unlikely to respond to one-size-fits-all treatments. Inflammation is recognized as an important phenotype of OA and is associated with worse pain and joint deterioration. Therefore, it is believed that anti-inflammatory treatments may be more effective for OA with an inflammatory phenotype. In this review, we summarized clinical trials that evaluated anti-inflammatory treatments for OA and discussed whether these treatments are more effective in inflammatory OA phenotypes compared to general OA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.